HRTX compared with KNSA: revenue, margins and what each company keeps, and the suppliers and customers both name

HRTXHeron Therapeutics, Inc.

Mkt capRevenueRevenue

KNSAKiniksa Pharmaceuticals International, plc

Mkt capRevenueRevenue

Compare

HRTXHeron Therapeutics, Inc.

KNSAKiniksa Pharmaceuticals International, plc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

HRTX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±62.0%▼−31.74%×0.51

May 11 '26±32.7%▼−21.05%×0.65

Q1 FY26±34.8%▲+11.11%×0.32

Q3 FY25±24.3%▼−3.39%×0.14

KNSA2 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±13.9%▲+22.23%×1.60

Q2 FY26—▲+25.03%—

= impliedHRTX realized, solidKNSA realized, hatchedOne scale, both sides: full bar = 63%× = |realized| ÷ impliedspan: HRTX 279d · KNSA 91dSource: market data

HRTXHeron Therapeutics, Inc.

0.29▲+4.32%· post 0.29

Mkt cap$55.6MRevenue$38MQ2 FY26Revenue$155MFY25

KNSAKiniksa Pharmaceuticals International, plc

93.80▲+6.18%· post 94.50

ClosedNov 6 '26

Mkt cap$7.4BRevenue$286MQ3 FY26Revenue$678MFY25

Compare

ClosedNov 6 '26

HRTXHeron Therapeutics, Inc.

KNSAKiniksa Pharmaceuticals International, plc

0.29▲+4.32%post 0.29

Price

93.80▲+6.18%post 94.50

$55.6M

Mkt cap

$7.4B

Q2 FY26$38M

Revenue

$286MQ3 FY26

FY25$155M

Revenue

$678MFY25

HRTX0.29▲+4.32%vsKNSA93.80▲+6.18%ClosedNov 6 '26